Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across...
Via
Benzinga
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &...
Via
Benzinga
Chinese Growth Level
October 18, 2021
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.
Via
Talk Markets
Europe's Unicorns
October 15, 2021
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.
Via
Talk Markets
Multiple Bits Of Bad News
September 28, 2021
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser.
Via
Talk Markets
Eisai, Biogen Initiate Rolling Submission For New Alzheimer's Drug
September 28, 2021
Eisai Co Ltd (OTC: ESALY) began its application process for lecanemab (BAN2401) for early Alzheimer's disease using an accelerated approval pathway. Lecanemab...
Via
Benzinga
A Day Of Huge Market Moves
September 21, 2021
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority.
Via
Talk Markets
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
September 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...
Via
Benzinga
Pressure Day
September 13, 2021
Today a recovery came to markets with a particular impact on uranium shares.
Via
Talk Markets
A Weak Week
September 10, 2021
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants.
Via
Talk Markets
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
September 10, 2021
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Via
Benzinga
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma
September 07, 2021
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-...
Via
Benzinga
Mu - The Newest Worry
September 03, 2021
Today London and New York fell on the huge drop in new employment levels in August.
Via
Talk Markets
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
August 31, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Amid Medicare Uncertainty, Biogen Offers Its Alzheimer's Drug For Free
August 30, 2021
Biogen Inc (NASDAQ: BIIB) is providing its controversial and expensive new Alzheimer's drug, free of charge for some patients amid slow claim reviews by Medicare, ...
Via
Benzinga
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and...
Via
Talk Markets
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
August 29, 2021
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (...
Via
Benzinga
What This Label Expansion Means for Merck
August 22, 2021
The Keytruda-Lenvima combo was recently approved for its second oncology indication.
Via
The Motley Fool
Exposures
Product Safety
White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
August 20, 2021
The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people...
Via
Benzinga
Exposures
Product Safety
Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei's
August 17, 2021
Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300...
Via
Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
August 15, 2021
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
August 15, 2021
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
Biogen's New Alzheimer's Drug Turned Away By Veterans Affairs
August 12, 2021
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer's drug developed by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC:...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
August 02, 2021
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...
Via
Benzinga
News Overload
July 29, 2021
Today US markets managed a rally despite misses in both the growth and employment data.
Via
Talk Markets
Full News Day
July 28, 2021
The US greatly increased its exports of liquified natural gas in the first half-year, to 9.6 billion cubic feet per day, a rise of 42% from a year earlier.
Via
Talk Markets
Topics
Energy
Exposures
Fossil Fuels
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
July 27, 2021
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ...
Via
Benzinga
Containment Plan
July 23, 2021
Today the US decided to cut China risks.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.